These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 31264510)

  • 1. A novel approach to evaluate the pharmacodynamics of a selective dopamine D1/D5 receptor partial agonist (PF-06412562) in patients with stable schizophrenia.
    Arce E; Balice-Gordon R; Duvvuri S; Naylor M; Xie Z; Harel B; Kozak R; Gray DL; DeMartinis N
    J Psychopharmacol; 2019 Oct; 33(10):1237-1247. PubMed ID: 31264510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Neurofunctional Domains Approach to Evaluate D1/D5 Dopamine Receptor Partial Agonism on Cognition and Motivation in Healthy Volunteers With Low Working Memory Capacity.
    Balice-Gordon R; Honey GD; Chatham C; Arce E; Duvvuri S; Naylor MG; Liu W; Xie Z; DeMartinis N; Harel BT; Braley GH; Kozak R; Park L; Gray DL
    Int J Neuropsychopharmacol; 2020 May; 23(5):287-299. PubMed ID: 32055822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A proof-of-concept, randomized controlled trial of DAR-0100A, a dopamine-1 receptor agonist, for cognitive enhancement in schizophrenia.
    Girgis RR; Van Snellenberg JX; Glass A; Kegeles LS; Thompson JL; Wall M; Cho RY; Carter CS; Slifstein M; Abi-Dargham A; Lieberman JA
    J Psychopharmacol; 2016 May; 30(5):428-35. PubMed ID: 26966119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The D1/D5 Dopamine Partial Agonist PF-06412562 in Advanced-Stage Parkinson's Disease: A Feasibility Study.
    Huang X; Lewis MM; Van Scoy LJ; De Jesus S; Eslinger PJ; Arnold AC; Miller AJ; Fernandez-Mendoza J; Snyder B; Harrington W; Kong L; Wang X; Sun D; Delnomdedieu M; Duvvuri S; Mahoney SE; Gray DL; Mailman RB
    J Parkinsons Dis; 2020; 10(4):1515-1527. PubMed ID: 32986682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A single 20 mg dose of dihydrexidine (DAR-0100), a full dopamine D1 agonist, is safe and tolerated in patients with schizophrenia.
    George MS; Molnar CE; Grenesko EL; Anderson B; Mu Q; Johnson K; Nahas Z; Knable M; Fernandes P; Juncos J; Huang X; Nichols DE; Mailman RB
    Schizophr Res; 2007 Jul; 93(1-3):42-50. PubMed ID: 17467956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Dopamine D1 Receptor Partial Agonist, PF-06669571, in Subjects with Idiopathic Parkinson's Disease.
    Gurrell R; Duvvuri S; Sun P; DeMartinis N
    Clin Drug Investig; 2018 Jun; 38(6):509-517. PubMed ID: 29478239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Randomized Trial to Assess the Efficacy and Safety of ABT-126, a Selective α7 Nicotinic Acetylcholine Receptor Agonist, in the Treatment of Cognitive Impairment in Schizophrenia.
    Haig GM; Bain EE; Robieson WZ; Baker JD; Othman AA
    Am J Psychiatry; 2016 Aug; 173(8):827-35. PubMed ID: 26940805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of the α7-Nicotinic Acetylcholine Receptor Agonist ABT-126 in the Treatment of Cognitive Impairment Associated With Schizophrenia: Results From a Phase 2b Randomized Controlled Study in Smokers.
    Haig GM; Wang D; Zhao J; Othman AA; Bain EE
    J Clin Psychiatry; 2018; 79(3):. PubMed ID: 28922590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopamine D1R Receptor Stimulation as a Mechanistic Pro-cognitive Target for Schizophrenia.
    Abi-Dargham A; Javitch JA; Slifstein M; Anticevic A; Calkins ME; Cho YT; Fonteneau C; Gil R; Girgis R; Gur RE; Gur RC; Grinband J; Kantrowitz J; Kohler C; Krystal J; Murray J; Ranganathan M; Santamauro N; Van Snellenberg J; Tamayo Z; Wolf D; ; Gray D; Lieberman J
    Schizophr Bull; 2022 Jan; 48(1):199-210. PubMed ID: 34423843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of the D1 dopamine receptor agonist dihydrexidine (DAR-0100A) on working memory in schizotypal personality disorder.
    Rosell DR; Zaluda LC; McClure MM; Perez-Rodriguez MM; Strike KS; Barch DM; Harvey PD; Girgis RR; Hazlett EA; Mailman RB; Abi-Dargham A; Lieberman JA; Siever LJ
    Neuropsychopharmacology; 2015 Jan; 40(2):446-53. PubMed ID: 25074637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the Efficacy, Safety, and Tolerability of BI 409306, a Novel Phosphodiesterase 9 Inhibitor, in Cognitive Impairment in Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial.
    Brown D; Nakagome K; Cordes J; Brenner R; Gründer G; Keefe RSE; Riesenberg R; Walling DP; Daniels K; Wang L; McGinniss J; Sand M
    Schizophr Bull; 2019 Mar; 45(2):350-359. PubMed ID: 29718385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential effects of D1 and D2 dopamine agonists on memory, motivation, learning and response time in non-human primates.
    Marino RA; Levy R
    Eur J Neurosci; 2019 Jan; 49(2):199-214. PubMed ID: 30326151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of D1/D5 Partial Agonist PF-06412562 in Parkinson's Disease following Oral Administration.
    Papapetropoulos S; Liu W; Duvvuri S; Thayer K; Gray DL
    Neurodegener Dis; 2018; 18(5-6):262-269. PubMed ID: 30453303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Task-related fMRI responses to a nicotinic acetylcholine receptor partial agonist in schizophrenia: A randomized trial.
    Barch DM; Marder SR; Harms MP; Jarskog LF; Buchanan RW; Cronenwett W; Chen LS; Weiss M; Maguire RP; Pezous N; Feuerbach D; Lopez-Lopez C; Johns DR; Behrje RB; Gomez-Mancilla B
    Prog Neuropsychopharmacol Biol Psychiatry; 2016 Nov; 71():66-75. PubMed ID: 27371157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Memantine augmentation in clozapine-refractory schizophrenia: a randomized, double-blind, placebo-controlled crossover study.
    Veerman SR; Schulte PF; Smith JD; de Haan L
    Psychol Med; 2016 Jul; 46(9):1909-21. PubMed ID: 27048954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of D1 receptors affects human reactivity and flexibility to valued cues.
    Soutschek A; Kozak R; de Martinis N; Howe W; Burke CJ; Fehr E; Jetter A; Tobler PN
    Neuropsychopharmacology; 2020 Apr; 45(5):780-785. PubMed ID: 31962344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-Related Target Occupancy and Effects on Circuitry, Behavior, and Neuroplasticity of the Glycine Transporter-1 Inhibitor PF-03463275 in Healthy and Schizophrenia Subjects.
    D'Souza DC; Carson RE; Driesen N; Johannesen J; Ranganathan M; Krystal JH;
    Biol Psychiatry; 2018 Sep; 84(6):413-421. PubMed ID: 29499855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an α7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia.
    Keefe RS; Meltzer HA; Dgetluck N; Gawryl M; Koenig G; Moebius HJ; Lombardo I; Hilt DC
    Neuropsychopharmacology; 2015 Dec; 40(13):3053-60. PubMed ID: 26089183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 1 Parkinson's Disease Studies Show the Dopamine D1/D5 Agonist PF-06649751 is Safe and Well Tolerated.
    Sohur US; Gray DL; Duvvuri S; Zhang Y; Thayer K; Feng G
    Neurol Ther; 2018 Dec; 7(2):307-319. PubMed ID: 30361858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered brainstem responses to modafinil in schizophrenia: implications for adjunctive treatment of cognition.
    Minzenberg MJ; Yoon JH; Soosman SK; Carter CS
    Transl Psychiatry; 2018 Mar; 8(1):58. PubMed ID: 29507283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.